A specific binding molecule having the property of binding to GLSPTVWLSV (SEQ ID NO: 1) HLA-A*02 complex and/or GLSPTVWLSA (SEQ ID No: 17) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain each of which comprises FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 where FR is a framework region and CDR is a complementarity determining region, wherein the specific binding molecule has one of the following combinations of alpha chain and beta chain CDRs: a) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LNHGY (SEQ ID NO: 26), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGVLFF (SEQ ID NO: 30), respectively; b) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MSHGY (SEQ ID NO: 27), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; c) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MNHEY (SEQ ID NO: 21), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGLLFF (SEQ ID NO: 32), respectively; d) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MNHEY (SEQ ID NO: 21), SLGAGI (SEQ ID NO: 29) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; e) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LSHGY (SEQ ID NO: 28), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; f) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSDGD (SEQ ID NO: 24) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MSHGY (SEQ ID NO: 27), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; or g) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSDGD (SEQ ID NO: 24) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LSHGY (SEQ ID NO: 28), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively, wherein the alpha chain variable domain framework regions comprise the following sequences: FR1 - amino acids 1-26 of SEQ ID NO: 2 FR2 - amino acids 33-49 of SEQ ID NO: 2 FR3 - amino acids 56-88 of SEQ ID NO: 2 FR4 - amino acids 102-111 of SEQ ID NO: 2 or respective sequences having at least 90% identity to said sequences, and the beta chain variable domain framework regions comprise the following sequences: FR1 - amino acids 1-26 of SEQ ID NO: 3 FR2 - amino acids 32-48 of SEQ ID NO: 3 FR3 - amino acids 55-90 of SEQ ID NO: 3 FR4 - amino acids 106-114 of SEQ ID NO: 3 or respective sequences having at least 90% identity to said sequences. a) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LNHGY (SEQ ID NO: 26), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGVLFF (SEQ ID NO: 30), respectively; b) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MSHGY (SEQ ID NO: 27), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; c) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MNHEY (SEQ ID NO: 21), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGLLFF (SEQ ID NO: 32), respectively; d) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MNHEY (SEQ ID NO: 21), SLGAGI (SEQ ID NO: 29) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; e) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSNGD (SEQ ID NO: 19) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LSHGY (SEQ ID NO: 28), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; f) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSDGD (SEQ ID NO: 24) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of MSHGY (SEQ ID NO: 27), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively; or g) alpha chain CDR1, CDR2 and CDR3 sequences of DRGSQS (SEQ ID NO: 18), IYSDGD (SEQ ID NO: 24) and CAARNYKTDLLIF (SEQ ID NO: 25), respectively, and beta chain CDR1, CDR2 and CDR3 sequences of LSHGY (SEQ ID NO: 28), SVGAGI (SEQ ID NO: 22) and CASSYATGGTGDLFF (SEQ ID NO: 31), respectively, FR1 - amino acids 1-26 of SEQ ID NO: 2 FR2 - amino acids 33-49 of SEQ ID NO: 2 FR3 - amino acids 56-88 of SEQ ID NO: 2 FR4 - amino acids 102-111 of SEQ ID NO: 2 FR1 - amino acids 1-26 of SEQ ID NO: 3 FR2 - amino acids 32-48 of SEQ ID NO: 3 FR3 - amino acids 55-90 of SEQ ID NO: 3 FR4 - amino acids 106-114 of SEQ ID NO: 3